These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 26430811)

  • 21. The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.
    Stein CK; Pawlyn C; Chavan S; Rasche L; Weinhold N; Corken A; Buros A; Sonneveld P; Jackson GH; Landgren O; Mughal T; He J; Barlogie B; Bergsagel PL; Davies FE; Walker BA; Morgan GJ
    Oncotarget; 2017 Apr; 8(17):27854-27867. PubMed ID: 28427158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biology of multiple myeloma.
    Drach J; Kaufmann H; Urbauer E; Schreiber S; Ackermann J; Huber H
    J Cancer Res Clin Oncol; 2000 Aug; 126(8):441-7. PubMed ID: 10961386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 mutations in multiple myeloma.
    Paydaś S; Sahin B; Seyrek E; Zorludemir S
    Mol Pathol; 1997 Dec; 50(6):329. PubMed ID: 9536285
    [No Abstract]   [Full Text] [Related]  

  • 24. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.
    Billadeau D; Jelinek DF; Shah N; LeBien TW; Van Ness B
    Cancer Res; 1995 Aug; 55(16):3640-6. PubMed ID: 7627974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
    Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
    Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cytogenetic and molecular basis of multiple myeloma].
    Taniwaki M; Matsumoto Y
    Nihon Rinsho; 2007 Dec; 65(12):2179-86. PubMed ID: 18069258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response.
    Rowley M; Van Ness B
    Oncogene; 2002 Dec; 21(57):8769-75. PubMed ID: 12483530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
    Mikala G; Jákó J; Vályi-Nagy I
    Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
    Croonquist PA; Van Ness B
    Oncogene; 2005 Sep; 24(41):6269-80. PubMed ID: 16007202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic mutations and outcome in myeloma.
    Bagcchi S
    Lancet Oncol; 2015 Sep; 16(9):e434. PubMed ID: 26299605
    [No Abstract]   [Full Text] [Related]  

  • 31. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees.
    Willems PM; Kuypers AW; Meijerink JP; Holdrinet RS; Mensink EJ
    Leukemia; 1993 Jul; 7(7):986-91. PubMed ID: 8321049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
    Souliotis VL; Dimopoulos MA; Episkopou HG; Kyrtopoulos SA; Sfikakis PP
    DNA Repair (Amst); 2006 Aug; 5(8):972-85. PubMed ID: 16781199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.
    Mithraprabhu S; Khong T; Ramachandran M; Chow A; Klarica D; Mai L; Walsh S; Broemeling D; Marziali A; Wiggin M; Hocking J; Kalff A; Durie B; Spencer A
    Leukemia; 2017 Aug; 31(8):1695-1705. PubMed ID: 27899805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
    Kortüm KM; Langer C; Monge J; Bruins L; Zhu YX; Shi CX; Jedlowski P; Egan JB; Ojha J; Bullinger L; Kull M; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
    Ann Hematol; 2015 Jul; 94(7):1205-11. PubMed ID: 25743686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients.
    Austen B; Barone G; Reiman A; Byrd PJ; Baker C; Starczynski J; Nobbs MC; Murphy RP; Enright H; Chaila E; Quinn J; Stankovic T; Pratt G; Taylor AM
    Br J Haematol; 2008 Sep; 142(6):925-33. PubMed ID: 18573109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma.
    O'Donnell E; Mahindra A; Yee AJ; Nardi V; Birrer N; Horick N; Borger D; Finkelstein D; Iafrate JA; Raje N
    EBioMedicine; 2015 Jan; 2(1):71-3. PubMed ID: 26137536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
    Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
    Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Targets and New Agents in High-Risk Multiple Myeloma.
    Nooka AK; Lonial S
    Am Soc Clin Oncol Educ Book; 2016; 35():e431-41. PubMed ID: 27249751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
    Gralewski JH; Post GR; van Rhee F; Yuan Y
    Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.